ArticleCureus2025
Serum Lipid Abnormalities in Pre-malignant and Malignant Lesions of the Gall Bladder.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder pathology encompasses a spectrum from benign inflammation to aggressive malignancies, with gallbladder cancer (GBC) being one of the most lethal gastrointestinal cancers. Emerging evidence suggests that metabolic dysregulation, particularly lipid abnormalities, may drive carcinogenesis. However, the relationship between serum lipid profiles and gallbladder lesion progression remains poorly characterized.
objectiveThis study aimed to investigate serum lipid abnormalities across benign (n = 48), premalignant (n = 11), and malignant (n = 12) gallbladder lesions to identify potential metabolic biomarkers for early detection and risk stratification.
methodsA cross-sectional study was conducted on 71 cholecystectomy specimens (benign, premalignant, malignant) from April 2023 to March 2025. Histopathological evaluation categorized lesions, while fasting serum lipid profiles (total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL)) were analyzed using automated biochemical assays. Statistical analysis included ANOVA and Pearson correlation tests, with significance at p < 0.05.
resultsThe cohort (mean age: 48.7 ± 14.1 years) showed female predominance (77.5%). Malignant lesions presented at older ages (mean: 55.1 years) and exhibited significant hypertriglyceridemia (301.75 ± 85.69 mg/dL; p = 0.014) and elevated VLDL (54.82 ± 22.74 mg/dL; p = 0.052) compared to benign/premalignant groups. HDL was the lowest in malignancies (37.00 ± 9.05 mg/dL).
conclusionProgressive lipid derangements - particularly hypertriglyceridemia, elevated VLDL, and reduced HDL - are associated with malignant transformation in gallbladder lesions. Serum lipid profiling may serve as a non-invasive tool for risk stratification and early detection. These findings highlight the potential for metabolic interventions in high-risk populations, though further longitudinal studies are needed to establish causality and therapeutic implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.